Although the agent is substantially more costly, dostarlimab became cost-effective when its cost was reduced to $5489 per cycle. Keywords: cost-effectiveness; ...

Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer.

Jemperli (dostarlimab) is a programmed death receptor-1 (PD-1)-blocking antibody, for use in: It is available in vial form for intravenous infusion, containing ...

The cost of each dose of the drug is $11,000 (Rs. 8,54,119/-) € 19355 (Rs 16,07,316/-) and Rs. 3.4 lakh/vial in India. Is this amount affordable by all members ...

Nov 4, 2022 ... In one-way sensitivity analyses, dostarlimab was cost-effective when its cost was reduced to $4905 (52% reduction). These results were robust in ...

Jun 20, 2024 ... Dostarlimab in combination with chemotherapy was cost-effective for primary advanced or recurrent dMMR EC from the perspective of a United States payer.

Jun 8, 2022 ... ... Dostarlimab costs nearly ₹ 8.55 lakh per dose. (Representational). A study has found that a drug named Dostarlimab has helped treat rectal ...

According to the clinical experts we consulted, patients with primary advanced or recurrent dMMR or MSI-H endometrial cancer experience poor response rates to ...

Dostarlimab is associated with greater survival compared with other treatments for women with recurrent dMMR endometrial cancer. However, the agent is ...

Jul 31, 2023 ... Drugs.com lists dostarlimab's price at $11,712.66 for 500 mg/10 mL intravenous solution. M. Alexander Otto is a physician assistant with a ...